TB-500 Benefits, Risks, and Side Effects: What You Need to Know

TB-500 is an experimental peptide promoted for wound healing, injury recovery, reduced inflammation, and improved mobility. However, most claims about TB-500 are based on laboratory research, animal studies, or research involving full-length thymosin beta-4, which is a different molecule.

The key point: TB-500 is not currently an FDA-approved medication. There are no adequate human clinical trials demonstrating that it safely heals muscle, tendon, ligament, or skin injuries. Its established side-effect profile, long-term risks, and appropriate dosage remain unknown.

In July 2026, an FDA advisory committee recommended that TB-500-related substances be added to the Section 503A Bulks List. That recommendation concerns eligibility for certain forms of pharmacy compounding. It does not mean that TB-500 received FDA approval or was proven safe and effective.

TB-500 at a Glance

• What it is: A synthetic seven-amino-acid peptide associated with a fragment of thymosin beta-4
• What it is promoted for: Wound healing, tendon recovery, muscle recovery, reduced inflammation, and mobility

• FDA-approved status: Not approved
• Human evidence: The FDA identified no adequate human clinical studies administering TB-500
• Known side effects: No established human side-effect profile
• Use reviewed by the FDA: Wound healing
• Advisory committee outcome: The committee recommended inclusion on the 503A Bulks List
• Final FDA decision: The advisory recommendation is not the same as final agency action

What Is TB-500?

TB-500 is generally described as a synthetic peptide related to amino acids 17 through 23 of thymosin beta-4.

The seven-amino-acid sequence associated with TB-500 is often written as LKKTETQ. Research identifying marketed TB-500 products has described an acetylated version of this sequence, known as Ac-LKKTETQ.

Thymosin beta-4 is a naturally occurring protein made up of 43 amino acids. It is found in many tissues and participates in biological processes involving:

• Actin regulation
• Cell movement
• Tissue remodeling
• Inflammatory signaling
• Blood-vessel formation
• Wound repair

TB-500 is much smaller than full-length thymosin beta-4. This distinction is central to understanding the evidence.

A study involving thymosin beta-4 cannot automatically establish that TB-500 has the same biological activity, tissue distribution, effectiveness, or safety. The two compounds differ substantially in size and structure.

Researchers originally identified the seven-amino-acid fragment in a product marketed as TB-500 using laboratory mass-spectrometry testing. Read the TB-500 identification study through the National Library of Medicine.

Is TB-500 FDA Approved?

No. TB-500 is not an FDA-approved drug for wound healing, tendon injuries, muscle recovery, athletic performance, or any other medical condition.

The FDA has not approved a standardized TB-500:

• Medical indication
• Dosage
• Injection schedule
• Treatment duration
• Manufacturing specification
• Side-effect profile
• Contraindication list
• Drug-interaction profile

Products sold online as TB-500, including products marked “research use only,” should not be treated as approved medications.

FDA approval normally requires controlled human trials, standardized manufacturing, toxicology testing, stability data, dose evaluation, and evidence that a drug’s benefits outweigh its risks for a specific condition. TB-500 has not completed that process.

What Did the FDA Review About TB-500?

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed TB-500 free base and TB-500 acetate for possible inclusion on the 503A Bulks List.

The specific proposed use evaluated by the FDA was wound healing.

FDA staff concluded before the meeting that available evidence did not establish the effectiveness of TB-500 for wound healing. The agency also reported that it had not identified human clinical studies in which TB-500 was administered to participants.

FDA staff recommended against adding the TB-500-related substances to the list because of:

• Inadequate evidence of clinical effectiveness
• Lack of human safety data
• Insufficient nonclinical toxicology information
• Uncertainty about peptide impurities
• Potential peptide aggregation
• Potential immune reactions
• Lack of evidence demonstrating a clinical need

The full scientific assessment is available in the FDA briefing document for TB-500-related bulk drug substances.

What Did the FDA Advisory Committee Decide?

The advisory committee voted on July 23, 2026, to recommend including the TB-500-related substances on the 503A Bulks List.

Eight committee members voted in favor, six voted against, and one abstained.

The vote was advisory. The FDA is not legally required to follow it and had not announced a final regulatory decision at the time this article was prepared.

Inclusion on the 503A Bulks List would not:

• Make TB-500 an FDA-approved drug
• Prove that it heals wounds or sports injuries
• Validate doses promoted online
• Approve research-chemical products for human use
• Establish a complete safety profile
• Allow unrestricted mass production or marketing

Section 503A generally concerns patient-specific medications prepared by qualifying compounding pharmacies under applicable federal and state requirements. The FDA’s guidance on the 503A Bulks List explains how this pathway differs from conventional drug approval.

For more context on the full meeting, read AlphaMD’s report on the FDA peptide-compounding votes involving BPC-157, TB-500, KPV, and MOTS-c.

What Are the Potential Benefits of TB-500?

TB-500 is marketed for several possible benefits, but these claims vary greatly in the quality of evidence supporting them.

Wound healing

Wound healing is the proposed use the FDA evaluated.

Animal and laboratory research involving thymosin beta-4 and related peptide fragments suggests that this biological pathway may affect:

• Cell migration
• Collagen organization
• Inflammatory responses
• Formation of new blood vessels
• Movement of skin cells into an injured area

One animal study found that the seven-amino-acid sequence LKKTETQ promoted dermal wound repair in aged and diabetic mice.

This finding supports further research, but a positive result in mice does not establish that injected TB-500 safely accelerates wound healing in humans. Review the animal wound-healing study.

Tendon and ligament recovery

TB-500 is widely promoted for tendon and ligament injuries, including strains, tendinopathy, and partial tears.

The rationale usually comes from thymosin beta-4 research involving cell migration, actin regulation, and tissue repair. However, the FDA did not identify adequate human clinical studies showing that TB-500:

• Repairs tendon fibers
• Heals ligament tears
• Shortens rehabilitation
• Prevents reinjury
• Improves surgical outcomes

Reduced discomfort would also not prove that damaged tissue has structurally healed.

Muscle recovery

Some athletes and fitness-focused users claim that TB-500 reduces soreness or accelerates muscle recovery.

There are no adequate controlled human trials demonstrating that TB-500 repairs muscle tears, reduces exercise-related damage, or allows a safe return to training sooner.

Post-exercise soreness usually improves naturally. Testimonials cannot determine whether an improvement resulted from TB-500, rest, rehabilitation, reduced activity, another treatment, or the normal passage of time.

Reduced inflammation

Thymosin beta-4 and some derived sequences have demonstrated effects on inflammatory pathways in experimental research.

That does not establish TB-500 as an anti-inflammatory medication in humans. Inflammation is also a normal part of tissue repair, so altering the inflammatory response may not always be beneficial.

Improved mobility or flexibility

Online reports sometimes describe improved flexibility, mobility, or range of motion after TB-500 use.

These reports are anecdotal. Improved movement may result from reduced pain or inflammation without correction of the underlying injury.

A tendon, ligament, or joint problem should be evaluated based on symptoms, physical examination, and imaging when appropriate, rather than whether a peptide temporarily changes how the area feels.

Does TB-500 Actually Work?

There is not enough human evidence to conclude that TB-500 works for wound healing or injury recovery.

The key evidence gap: The FDA reported that it found no clinical studies administering TB-500 to humans. Research involving cells, rodents, horses, full-length thymosin beta-4, or other peptide fragments cannot replace controlled studies of TB-500 in human patients.

The existing evidence can be understood this way:

• Cell research may identify possible biological mechanisms, but it cannot establish human effectiveness or safety.
• Animal research may show an effect in an experimental model, but humans may not respond the same way.
• Thymosin beta-4 studies provide information about the full 43-amino-acid molecule, not direct proof that seven-amino-acid TB-500 works.
• User testimonials describe personal experiences but cannot establish causation, product identity, or safety.
• Controlled human trials of TB-500 would be needed to determine clinical effectiveness, but adequate trials are not currently available.

Full-length thymosin beta-4 has undergone limited human investigation, including topical wound research. Those studies may help researchers understand the broader biological pathway, but they should not be used to claim that TB-500 has been clinically proven.

What Are the Side Effects of TB-500?

TB-500 does not have an established human side-effect profile.

That does not mean it has no side effects. It means systematic human research has not adequately identified:

• Common adverse effects
• Rare but serious adverse effects
• Dose-related reactions
• Long-term complications
• Drug interactions
• Risks in specific medical conditions

The FDA reported that it had not identified human exposure data or adverse-event reports clearly attributable to TB-500 in its review.

An absence of reports is not proof of safety, particularly when product use may occur outside regulated clinical systems.

What Are the Main Risks of TB-500?

Immune reactions

Peptides can potentially trigger immune responses. Risk may be affected by the peptide itself, its formulation, degradation, aggregation, or manufacturing impurities.

Possible immune-related concerns include:

• Local swelling
• Rash
• Itching
• Hypersensitivity
• Antibody formation
• Inflammatory reactions

The probability and severity of these reactions with TB-500 are unknown.

Peptide aggregation and impurities

Peptides can degrade or group together during production and storage. These aggregates and related impurities may alter biological activity or increase the risk of an immune reaction.

The FDA identified aggregation, characterization, and impurity concerns as unresolved issues in its TB-500 assessment.

Incorrect identity or potency

An online vial labeled TB-500 may not necessarily contain the listed peptide at the stated concentration.

Possible quality problems include:

• Incorrect amino-acid sequence
• Too little active ingredient
• Too much active ingredient
• Undisclosed substances
• Degradation products
• Residual manufacturing chemicals

Microbial contamination

A product intended for injection must meet appropriate sterility and endotoxin standards.

Unregulated or improperly prepared products may expose users to:

• Bacteria
• Fungi
• Endotoxins
• Local infection
• Abscesses
• Systemic infection

The FDA explains that compounded drugs are not FDA approved and that contamination or incorrect potency can result in serious harm. Learn about the risks associated with compounded medications.

Injection complications

Risks associated with subcutaneous or intramuscular injection can include:

• Pain
• Bruising
• Bleeding
• Infection
• Tissue injury
• Nerve injury
• Incorrect administration

These route-related risks exist independently of the peptide’s biological effects.

Unknown long-term effects

There are insufficient data to determine whether repeated or long-term TB-500 exposure affects:

• Immune function
• Cardiovascular health
• Liver or kidney function
• Fertility
• Pregnancy
• Abnormal tissue growth
• Cancer risk
• Interactions with medications

The correct conclusion is not that TB-500 causes these outcomes. It is that available research cannot rule them in or out.

Is Injectable TB-500 Safe?

There is not enough evidence to conclude that injectable TB-500 is safe.

Human pharmacokinetic data are lacking. Pharmacokinetics refers to how a substance is absorbed, distributed, metabolized, and removed from the body.

Without adequate human studies, researchers cannot reliably determine:

• How long TB-500 remains active
• Which tissues receive the greatest exposure
• Whether effects accumulate with repeated doses
• Which dose produces toxicity
• Whether certain patients face greater risk

Product sterility and accurate concentration are additional concerns for any injectable peptide.

What Is the Correct TB-500 Dosage?

There is no FDA-approved or clinically established TB-500 dosage.

Schedules promoted by websites, forums, coaches, or wellness influencers have not been validated through a recognized drug-development program.

There is no established:

• Loading dose
• Maintenance dose
• Injection frequency
• Treatment cycle
• Injury-specific protocol
• Maximum safe dose
• Long-term dosing schedule

This article intentionally does not provide a TB-500 dosing protocol because doing so would imply a level of safety and clinical validation that does not currently exist.

Is TB-500 the Same as Thymosin Beta-4?

No. TB-500 and full-length thymosin beta-4 are related but distinct substances.

Key differences include:

• TB-500 consists of seven amino acids.
• Thymosin beta-4 consists of 43 amino acids.
• TB-500 is commonly described as a synthetic fragment related to amino acids 17 through 23.
• Thymosin beta-4 is a naturally occurring full-length protein.
• The FDA identified no adequate human studies administering TB-500.
• Limited topical and systemic human research involving thymosin beta-4 does exist.
• Results involving full-length thymosin beta-4 cannot automatically be assigned to TB-500.
• Neither is currently an FDA-approved wound-healing drug.

This distinction is one of the most important limitations in online discussions of TB-500.

Is TB-500 the Same as BPC-157?

No. TB-500 and BPC-157 are different experimental peptides.

TB-500:

• Consists of seven amino acids
• Is associated with thymosin beta-4 pathways and wound repair
• Was reviewed by the FDA for wound healing
• Is not FDA approved

BPC-157:

• Consists of 15 amino acids
• Is associated with gastrointestinal protection and tissue-repair models
• Was reviewed by the FDA for ulcerative colitis
• Is not FDA approved

The two peptides are sometimes combined in online “recovery stacks.” There are no adequate clinical trials establishing the safety, effectiveness, or interaction profile of this combination.

Is TB-500 Prohibited in Competitive Sports?

Competitive athletes should be aware that TB-500 is prohibited under anti-doping rules.

The World Anti-Doping Agency’s 2026 Prohibited List took effect on January 1, 2026. Athletes remain responsible for prohibited substances found in their bodies, even when a product is obtained from a clinic, coach, or online supplier.

Review the current World Anti-Doping Agency Prohibited List.

Frequently Asked Questions About TB-500

Is TB-500 a steroid?

No. TB-500 is a synthetic peptide, not an anabolic steroid, testosterone product, or growth hormone. Its legal, regulatory, and safety status should still be evaluated independently. Being a peptide does not mean that it is automatically safe or approved for human use.

Can TB-500 heal a torn tendon?

There are no adequate human clinical trials showing that TB-500 heals a torn tendon. Tendon tears vary in severity and may require activity modification, physical therapy, imaging, immobilization, or surgery. Reduced pain after using any substance does not confirm that the tendon has structurally healed.

How quickly does TB-500 work?

There is no clinically established timeline for TB-500 because controlled human studies have not determined whether it works for injury recovery. Timelines promoted online are generally based on testimonials rather than validated clinical outcomes.

Does TB-500 build muscle?

There is no reliable evidence that TB-500 directly builds muscle or increases strength. It is generally promoted for recovery, but even those claims have not been established in adequate human trials.

Is pharmacy-compounded TB-500 FDA approved?

No. A compounded medication is not FDA approved. Inclusion of a bulk substance on the 503A Bulks List would allow certain qualifying compounding uses under specific conditions, but the FDA would not review each compounded product for safety, effectiveness, or manufacturing quality before dispensing.

Did the FDA approve TB-500 in July 2026?

No. An FDA advisory committee recommended adding TB-500-related substances to the 503A Bulks List. The recommendation was nonbinding, and the FDA retained authority to make the final decision. The vote did not constitute drug approval.

The Bottom Line

TB-500 is an experimental seven-amino-acid peptide promoted for wound healing and recovery from tendon, ligament, and muscle injuries.

Laboratory and animal findings provide a reason to continue studying the peptide, but they do not establish that TB-500 is effective or safe in humans. The FDA found no adequate human clinical studies administering TB-500 and identified unresolved concerns involving safety, impurities, aggregation, and immune reactions.

The July 2026 advisory committee recommendation may affect whether qualifying pharmacies can eventually prepare certain patient-specific compounded formulations. It does not make TB-500 FDA approved or validate the products and protocols promoted online.

Persistent pain, weakness, swelling, loss of motion, or suspected tissue injury should be evaluated by a licensed medical provider rather than treated solely on the basis of peptide marketing or anecdotal reports.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. TB-500 is not currently an FDA-approved drug. Speak with a licensed medical provider before using any medication, peptide, supplement, or injectable product.